QURE has been in the news 1200% more than usual
Feb 14, 2026, 3:32 AM
-24.26%
What does QURE do
uniQure NV, headquartered in Amsterdam, specializes in gene therapies and employs 480 staff, focusing on one-time treatments for genetic diseases. Their lead candidates include AMT-061 for hemophilia B and AMT-130 for Huntington's disease.
QURE has been in the news recently: Multiple law firms, including Schall Law Firm and DJS Law Group, have filed securities lawsuits alleging uniQure N.V. made false statements and violated Exchange Act provisions (Section 10(b)/20(a)) affecting investors who bought its stock between September 24 and October 31, 2025. Investors who purchased uniQure shares during that period must file or contact counsel by April 13, 2026 if they wish to seek lead‑plaintiff status or recover damages.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.